Population diversity and the performance of warfarin dosing algorithms

British Journal of Clinical Pharmacology

Volumn 72, Issue 3, 2011, Pages 451-453

  Suarez Kurtz, Guilherme ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CARBAMAZEPINE; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ALGORITHM; ALLELE; ANTICOAGULATION; DRUG DOSE REGIMEN; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HUMAN; NOTE; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 79961135011     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04018.x     Document Type: Note

References (12)

1. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-31.
2. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
3. Caulfield T, Fullerton SM, Ali-Khan SE, Arbour L, Burchard EG, Cooper RS, Hardy BJ, Harry S, Hyde-Lay R, Kahn J, Kittles R, Koenig BA, Lee SS, Malinowski M, Ravitsky V, Sankar P, Scherer SW, Séguin B, Shickle D, Suarez-Kurtz G, Daar AS. Race and ancestry in biomedical research: exploring the challenges. Genome Med 2009; 1: 8.
4. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 445-51.
5. Scott SA, Jarenko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RL. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009; 10: 1243-55.
6. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ, International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-34.
7. Botton M, Bandinelli E, Rohde L, Amon L, Hutz M. Influence of genetic, biological and pharmacological facrtors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011.
8. Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front Pharmacogenetics 2010; 1: article 118, 1-10.
9. Suarez-Kurtz G, Perini JA, Silva-Assunção E, Struchiner CJ. Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose. Blood 2009; 113: 4125-6.
10. Perini JA, Struchiner CJ, Silva-Assunção E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 2008; 84: 722-8.
11. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
12. Hatch E, Wynne H, Avery P, Wadelius M, Kamali F. Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients. J Thromb Haemost 2008; 6: 1038-40.